Drug
Pilabactam clinical trials
Includes 3 studies of Pilabactam sodium.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2023
Studies by the year they started
3 studies that test it; most in 2023 (1)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
Who runs them
Industry 3 · Other 0
Antabio (3)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses pilabactam is read from its arms, and is right about nine times in ten.
Testing it · 3
- Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult ParticipantsCompletedPhase 1AntabioNCT06916156Written as ANT3310
- Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired SubjectsCompletedPhase 1AntabioNCT06527677Written as ANT3310
- FiH Study to Assess Safety and PK of SAD and MAD of ANT3310 Alone and in Combination With Meropenem in Healthy SubjectsCompletedPhase 1AntabioNCT05905913Written as ANT3310
Codes
What other systems call pilabactam · ClinicalTrials.gg INT017263
- UNII (FDA) M7P8J9YDG9PILABACTAMConfirmed FDA, Wikidata
- Wikidata Q140529285pilabactamConfirmed FDA, Wikidata
- NCI Thesaurus C223296PilabactamOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | M7P8J9YDG9 | PILABACTAM | Confirmed FDA, Wikidata |
| Wikidata | Q140529285 | pilabactam | Confirmed FDA, Wikidata |
| NCI Thesaurus | C223296 | Pilabactam | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.